Use of Integrase Inhibitors in HIV-Infected Children and Adolescents

• Published in: Drugs (New York, N.Y.) Vol. 75; no. 13; pp. 1483 - 1497
• Main Authors: Dehority, Walter, Abadi, Jacobo, Wiznia, Andrew, Viani, Rolando M.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.09.2015; Springer Nature B.V
• Subjects: Adolescent; Adult; Adults; Age Factors; Child; Children & youth; Clinical trials; Drug Approval; Drug resistance; Drug Resistance, Viral; Drug therapy; FDA approval; Heterocyclic Compounds, 3-Ring - adverse effects; Heterocyclic Compounds, 3-Ring - pharmacology; Heterocyclic Compounds, 3-Ring - therapeutic use; HIV; HIV Infections - drug therapy; HIV Infections - virology; HIV Integrase Inhibitors - adverse effects; HIV Integrase Inhibitors - pharmacology; HIV Integrase Inhibitors - therapeutic use; Human immunodeficiency virus; Humans; Immunology; Infections; Internal Medicine; Medicine; Medicine & Public Health; Pediatrics; Pharmacology/Toxicology; Pharmacotherapy; Quinolones - adverse effects; Quinolones - pharmacology; Quinolones - therapeutic use; Raltegravir Potassium - adverse effects; Raltegravir Potassium - pharmacology; Raltegravir Potassium - therapeutic use; Review Article; United States > US; Tenofovir; Rifabutin; Atazanavir; Efavirenz; Virological Failure
• ISSN: 0012-6667; 1179-1950
• DOI: 10.1007/s40265-015-0446-2

Resistance to antiretroviral drugs is an increasingly prevalent challenge affecting both the adult and pediatric HIV-infected populations. Though data on the safety, pharmacokinetics, and efficacy of newer antiretroviral agents in children typically lags behind adult data, newer agents are becoming available for use in HIV-infected children who are failing to respond to or are experiencing toxicities with traditional antiretroviral regimens. Integrase strand transfer inhibitors are one such new class of antiretrovirals. Raltegravir has been US Food and Drug Administration (FDA) approved for use in patients over the age of 4 weeks. Elvitegravir is a second member of this class, and has the potential for use in children but does not yet have a Pediatric FDA indication. Dolutegravir, a second-generation integrase inhibitor, is approved for those older than 12 years. This review summarizes the use of integrase inhibitors in children and adolescents, and highlights the results of recent clinical trials.